<DOC>
	<DOCNO>NCT00329472</DOCNO>
	<brief_summary>This study randomize phase III trial design ass whether ( preoperative ) neoadjuvant chemotherapy follow surgery plus adjuvant chemotherapy gemcitabine cisplatin ( experimental treatment ) improve 3-year disease-free survival , compare surgery plus adjuvant chemotherapy gemcitabine cisplatin ( standard treatment ) stage IB , IIA , IIB T3N1 non-small cell lung cancer</brief_summary>
	<brief_title>Efficacy Study Induction Chemotherapy Before Surgery Operable Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically cytologically proven NSCLC patient All patient must : Clinical stage IB , IIA , IIB T3N1 mediastinoscopy , Chest CT PETCT 18 year age older ECOG performance status 01 Unidimensionally measurable lesion RECIST criteria No prior chemotherapy radiotherapy NSCLC Preoperative FEV1 ≥ 2.0 L evaluate within 28 day Adequate bone marrow function : Hb &gt; 9.0 g/dL , WBC ≥ 4,000/μL , platelet count ≥ 100,000/μL Adequate liver renal function : Total bilirubin &lt; 2 x ULN , AST/ALT &lt; 3 x ULN , serum creatinine ≤ 1.5 mg/dL , creatinine clearance ≥ 60 mL/min Written inform consent Superior sulcus tumor Prior malignancy except adequately treat basal cell squamous cell skin cancer situ cervical cancer least 5 year Uncontrolled systemic illness DM , CHF , unstable angina arrhythmia Recent myocardial infarction within 6 month Patients postobstructive pneumonia serious infection Pregnant nursing woman ( Women reproductive potential agree use effective contraceptive method . ) Patients psychological problem</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>